AlveoGene debuts to develop inhaled gene therapy technology

Today saw the debut of a new UK-based biotech, called AlveoGene, which has been formed to develop therapies based on a lentiviral vector platform used to deliver gene therapies directly into the lungs, developed by researchers from the UK Respiratory Gene Therapy Consortium (GTC).